Related Experiment Videos
[Putrescine in evaluation of the leukemic process in children]
Insights
Elevated urinary putrescine indicates active leukemia proliferation in children. This biomarker can predict disease relapse in patients during remission.
Area of Science:
- Biochemistry
- Pediatric Oncology
- Clinical Chemistry
Background:
- Acute leukemia involves uncontrolled proliferation of immature white blood cells.
- Biomarkers are crucial for monitoring disease activity and predicting outcomes in leukemia.
- Putrescine, a polyamine, plays a role in cell growth and proliferation.
Purpose of the Study:
- To investigate the relationship between urinary putrescine levels and acute leukemia activity.
- To determine if putrescine presence in urine, blood, and bone marrow correlates with leukemic proliferation.
- To assess the potential of urinary putrescine as an early indicator of relapse in acute leukemia patients.
Main Methods:
- Analysis of urinary putrescine levels in 44 children with active acute leukemia.
- Assessment of putrescine presence in blood and bone marrow samples.
- Correlation of putrescine levels with disease course and relapse status.
Main Results:
- Elevated urinary putrescine levels (66.3 +/- 5.1 mumols/day) were observed in children with active acute leukemia.
- The presence of putrescine in urine, blood, and bone marrow correlated with activated leukemic proliferation.
- Higher putrescine levels were associated with a more active disease course.
Conclusions:
- Urinary putrescine serves as a marker for activated leukemic proliferation in pediatric acute leukemia.
- Putrescine's presence in biological samples confirms its role in the disease process.
- Urinary putrescine shows potential as an early predictor of relapse in leukemia patients, even during remission.
Abstract:
Relationship between elevated putrescine level in urine and its presence in the blood and bone marrow was analyzed in 44 children with acute leukemia in the active stage. It has been shown that putrescine is a marker of activation of leukemic proliferation that is confirmed by the disease course character in patients with elevated putrescine level in urine (66.3 +/- 5.1 mumols/day) and its presence in the blood and bone marrow. Putrescine can serve as an early precursor of relapses during investigation of patients in the remission state.